{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262519","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.821888+00:00","generated_at":"2026-05-17T00:52:37.186280+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed","bullets":["Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).","Phase 3 X-TOLE2 FOS study completed enrollment (380 patients); topline data expected early 2026.","Phase 3 MDD (X-NOVA2/3) and BPD (X-CEED) studies continue recruiting; Phase 1 Nav1.7 and Kv7 studies underway.","Tucker Kelly appointed CFO to lead finance strategy ahead of azetukalner launch.","Cash $555.3M as of Sept 30, 2025; runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262519","json":"https://secwatch.observer/filing/0001193125-25-262519.json","markdown":"https://secwatch.observer/filing/0001193125-25-262519.md","text":"https://secwatch.observer/filing/0001193125-25-262519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/0001193125-25-262519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/xene-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:52:37.186280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}